A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Infection, Human Immunodeficiency Virus I and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — May 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Shionogi
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
(Móstoles) Madrid, Spain, Alcalá de Henares, Spain, Alicante, Spain, Antwerp, Belgium, Augusta, United States, Aurora, United States, Badalona, Spain, Bagno A Ripoli (FI), Italy, Bakersfield, United States, Baltimore, United States and 104 more location s